Alpha 2.0
Login Register
» Articles » PMID: 35045201

Real-world Applicability of Commercial Chimeric Antigen Receptor T-cell Therapy Among Older Adults with Relapsed And/or Refractory Multiple Myeloma

Overview
Journal Am J Hematol
Specialty Hematology
Date 2022 Jan 19
PMID 35045201
Authors
Smith Giri
Susan Bal
Kelly N Godby
Gayathri Ravi
Deanna Clark
Clare Ubersax
Abigail Cooley
Priscila White
Sunil Rangarajan
Grant R Williams
Luciano J Costa
Affiliations
Soon will be listed here.
Citing Articles

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.

Ho P, Quach H, Sidiqi M, Lee C, Butler J, Spencer A Front Oncol. 2025; 14:1535869.

PMID: 39906669 PMC: 11790593. DOI: 10.3389/fonc.2024.1535869.

A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?.

Andrea A, Chiron A, Sarrabayrouse G, Bessoles S, Hacein-Bey-Abina S Front Immunol. 2024; 15:1459818.

PMID: 39430751 PMC: 11486669. DOI: 10.3389/fimmu.2024.1459818.

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.

Banerjee R, Biru Y, Cole C, Faiman B, Midha S, Ailawadhi S Blood Cancer J. 2024; 14(1):149.

PMID: 39191731 PMC: 11350150. DOI: 10.1038/s41408-024-01129-0.

Universal CAR 2.0 to overcome current limitations in CAR therapy.

Schlegel L, Werbrouck C, Boettcher M, Schlegel P Front Immunol. 2024; 15:1383894.

PMID: 38962014 PMC: 11219820. DOI: 10.3389/fimmu.2024.1383894.

New Strategies for the Treatment of Older Myeloma Patients.

Larocca A, Cani L, Bertuglia G, Bruno B, Bringhen S Cancers (Basel). 2023; 15(10).

PMID: 37345030 PMC: 10216689. DOI: 10.3390/cancers15102693.